Clinical	clinical	O	O	O	O
nephrotoxicity	nephrotoxicity	O	DISEASE	OTHERS	I
of	of	O	O	O	O
tobramycin	tobramycin	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
gentamicin	gentamicin	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

A	a	O	O	O	O
prospective	prospective	O	O	O	O
study	study	O	O	O	O
.	.	O	O	O	O

Nearly	nearly	O	O	O	O
3.2	3.2	O	O	O	O
million	million	O	O	O	O
people	people	O	O	O	O
in	in	O	O	O	O
this	this	O	O	O	O
country	country	O	O	O	O
receive	receive	O	O	O	O
aminoglycoside	aminoglycoside	CHEMICALS	O	OTHERS	I
antibiotics	antibiotics	O	O	O	O
annually	annually	O	O	O	O
.	.	O	O	O	O

Gentamicin	gentamicin	CHEMICALS	O	OTHERS	I
sulfate	sulfate	O	O	OTHERS	I
and	and	O	O	O	O
tobramycin	tobramycin	CHEMICALS	O	OTHERS	I
sulfate	sulfate	O	O	OTHERS	I
continue	continue	O	O	O	O
to	to	O	O	O	O
demonstrate	demonstrate	O	O	O	O
ototoxicity	ototoxicity	O	DISEASE	OTHERS	I
and	and	O	O	O	O
nephrotoxicity	nephrotoxicity	O	DISEASE	OTHERS	I
in	in	O	O	O	O
both	both	O	O	O	O
animal	animal	O	O	O	O
and	and	O	O	O	O
clinical	clinical	O	O	O	O
studies	studies	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
this	this	O	O	O	O
study	study	O	O	O	O
,	,	O	O	O	O
62	62	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
confirmed	confirmed	O	O	O	O
initial	initial	O	O	O	O
normal	normal	O	O	O	O
renal	renal	O	O	O	O
function	function	O	O	O	O
and	and	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
2	2	O	O	O	O
to	to	O	O	O	O
5	5	O	O	O	O
mg/kg/day	mg/kg/day	O	O	O	O
of	of	O	O	O	O
gentamicin	gentamicin	CHEMICALS	O	OTHERS	I
sulfate	sulfate	O	O	OTHERS	I
or	or	O	O	O	O
tobramycin	tobramycin	CHEMICALS	O	OTHERS	I
sulfate	sulfate	O	O	OTHERS	I
for	for	O	O	O	O
a	a	O	O	O	O
minimum	minimum	O	O	O	O
of	of	O	O	O	O
seven	seven	O	O	O	O
days	days	O	O	O	O
were	were	O	O	O	O
followed	followed	O	O	O	O
up	up	O	O	O	O
prospectively	prospectively	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
aminoglycoside-related	aminoglycoside-related	O	O	O	O
renal	renal	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
,	,	O	O	O	O
defined	defined	O	O	O	O
as	as	O	O	O	O
at	at	O	O	O	O
least	least	O	O	O	O
a	a	O	O	O	O
one-third	one-third	O	O	O	O
reduction	reduction	O	O	OTHERS	I
in	in	O	O	OTHERS	I
renal	renal	O	O	OTHERS	I
function	function	O	O	OTHERS	I
.	.	O	O	O	O

In	in	O	O	O	O
these	these	O	O	O	O
62	62	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
no	no	O	O	O	O
other	other	O	O	O	O
causes	causes	O	O	O	O
for	for	O	O	O	O
renal	renal	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
could	could	O	O	O	O
be	be	O	O	O	O
identified	identified	O	O	O	O
.	.	O	O	O	O

Five	five	O	O	O	O
of	of	O	O	O	O
33	33	O	O	O	O
(	(	O	O	O	O
15	15	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
tobramycin-treated	tobramycin-treated	O	O	O	O
patients	patients	O	O	O	O
and	and	O	O	O	O
16	16	O	O	O	O
of	of	O	O	O	O
29	29	O	O	O	O
(	(	O	O	O	O
55.2	55.2	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
gentamicin-treated	gentamicin-treated	O	O	O	O
patients	patients	O	O	O	O
had	had	O	O	O	O
renal	renal	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Thus	thus	O	O	O	O
,	,	O	O	O	O
gentamicin	gentamicin	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
renal	renal	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
more	more	O	O	O	O
than	than	O	O	O	O
three	three	O	O	O	O
times	times	O	O	O	O
as	as	O	O	O	O
often	often	O	O	O	O
as	as	O	O	O	O
was	was	O	O	O	O
tobramycin	tobramycin	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

